Reuters logo
4 个月内
BRIEF-Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial
2017年4月24日 / 中午11点50分 / 4 个月内

BRIEF-Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial

1 分钟阅读

April 24 (Reuters) - Akari Therapeutics Plc:

* Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial and in additional clinical targets

* Akari Therapeutics Plc - new preclinical data demonstrates positive response of coversin's combined c5 and ltb4 therapy in skin and eye models

* Akari Therapeutics Plc - phase 3 PNH program expected to commence in 4q2017

* Akari Therapeutics Plc - phase 2 programs in mucous membrane pemphigoid (eye) and bullous pemphigoid (skin) expected to commence in 1q2018

* Akari Therapeutics Plc- expects to initiate its phase 2 trial in AHUS in 2Q2017, and anticipates phase 2 ahus data 2Q2018.

* Akari Therapeutics Plc - anticipates initial phase 3 data for PNH in 1q2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below